Cleveland Diagnostics announced it raised $56.5 Million in an initial filing from an offering of $56.5 Million

Company

Location

About

Cleveland Diagnostics, Inc. is a cancer biotechnology company that has unlocked the diagnostics power of protein structural change. Its scientists are developing highly efficacious, lab-friendly, affordable diagnostics tests that use proprietary technology to detect cancer earlier. Cleveland Diagnostics’ portfolio of non-invasive cancer diagnostics will soon expand beyond its novel IsoPSA prostate cancer test to breast cancer, lung cancer, and other diseases.